Structure via PubChem · Public domain (PubChem)
atrasentan
Sign in to saveAlso known as A-127722, A-147627, ABT-627
Atrasentan, sold under the brand name Vanrafia, is a medication used to reduce proteinuria. It is an endothelin receptor antagonist. It is taken by mouth.
Chemical data
- Formula
- C29H38N2O6
- Molecular weight
- 510.6 g/mol
- IUPAC name
- (2R,3R,4S)-4-(1,3-benzodioxol-5-yl)-1-[2-(dibutylamino)-2-oxoethyl]-2-(4-methoxyphenyl)pyrrolidine-3-carboxylic acid
- SMILES
- CCCCN(CCCC)C(=O)CN1C[C@@H]([C@H]([C@@H]1C2=CC=C(C=C2)OC)C(=O)O)C3=CC4=C(C=C3)OCO4
- InChIKey
- MOTJMGVDPWRKOC-QPVYNBJUSA-N
- XLogP
- 2.4
- Polar surface area
- 88.5 Ų
- H-bond donors
- 1
- H-bond acceptors
- 7
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Phase 3
- Molecule type
- Small molecule
- Indications
- diabetic nephropathy, prostate adenocarcinoma, prostate cancer, IGA glomerulonephritis
via ChEMBL · EBI
Research
510 papers- Atrasentan in Patients with IgA Nephropathy.The New England journal of medicine · 2025
- Atrasentan: First Approval.Drugs · 2025
- Atrasentan.2006
- Atrasentan.2012
- Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial.Lancet (London, England) · 2019
via PubMed
Wikidata facts
- Subclass of
- carboxylic acid
- Mass
- 510.273
Show 5 more facts
- chemical formula
- C₂₉H₃₈N₂O₆
- isomeric SMILES
- CCCCN(CCCC)C(=O)CN1C[C@@H]([C@H]([C@@H]1C2=CC=C(C=C2)OC)C(=O)O)C3=CC4=C(C=C3)OCO4
- canonical SMILES
- CCCCN(CCCC)C(=O)CN1CC(C(C1C2=CC=C(C=C2)OC)C(=O)O)C3=CC4=C(C=C3)OCO4
- subject has role
- Endothelin receptor antagonist
- Commons category
- Atrasentan
Sources (2)
via Wikidata · CC0
~2 min read
Encyclopedic overview
9 sectionsContents
- Medical uses
- Society and culture
- Legal status
- Names
- Research
- Clinical trials
- See also
- References
- External links
Atrasentan, sold under the brand name Vanrafia, is a medication used to reduce proteinuria. It is an endothelin receptor antagonist. It is taken by mouth.
Atrasentan was approved for medical use in the United States for IgA nephropathy in April 2025.
Excerpted from Wikipedia’s “atrasentan” article, available under the CC BY-SA 4.0 licence.